226 related articles for article (PubMed ID: 34690666)
1. Estimating Global Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease in Overweight or Obese Children and Adolescents: Systematic Review and Meta-Analysis.
Liu J; Mu C; Li K; Luo H; Liu Y; Li Z
Int J Public Health; 2021; 66():1604371. PubMed ID: 34690666
[No Abstract] [Full Text] [Related]
2. Prevalence and associated factors of metabolic-associated fatty liver disease in overweight Finnish children and adolescents.
Riekki H; Aitokari L; Kivelä L; Lahti S; Hiltunen P; Vuorela N; Huhtala H; Lakka TA; Kurppa K
Front Endocrinol (Lausanne); 2023; 14():1090344. PubMed ID: 37409224
[TBL] [Abstract][Full Text] [Related]
3. Prevalence and incidence of MAFLD and associated anthropometric parameters among prepubertal children of the Shanghai Birth Cohort.
Zeng J; Jin Q; Yang J; Yang RX; Zhang RN; Zhao J; Fan JG
Hepatol Int; 2023 Dec; 17(6):1416-1428. PubMed ID: 37728728
[TBL] [Abstract][Full Text] [Related]
4. Associations of metal mixtures with metabolic-associated fatty liver disease and non-alcoholic fatty liver disease: NHANES 2003-2018.
Xie Z; Aimuzi R; Si M; Qu Y; Jiang Y
Front Public Health; 2023; 11():1133194. PubMed ID: 36950101
[TBL] [Abstract][Full Text] [Related]
5. Prevalence and Risk Factors of Metabolic Dysfunction-Associated Fatty Liver Disease with Renal Insufficiency in Overweight/Obese Adults.
Shi A; Deng J; Ma J; Yang L; Tantai X; Wang Q; Chang D; Wang J; Guo X; Lu X; Shi H
Obes Facts; 2023; 16(6):548-558. PubMed ID: 37640023
[TBL] [Abstract][Full Text] [Related]
6. Metabolic dysfunction-associated fatty liver disease in people living with HIV.
Michel M; Labenz C; Armandi A; Kaps L; Kremer WM; Galle PR; Grimm D; Sprinzl M; Schattenberg JM
Sci Rep; 2023 Jun; 13(1):9158. PubMed ID: 37280241
[TBL] [Abstract][Full Text] [Related]
7. Uric acid and sCD163 as biomarkers for metabolic dysfunction and MAFLD in children and adolescents with overweight and obesity.
Orry S; Dalstrup Jakobsen D; Kristensen NM; Meldgaard Bruun J
J Pediatr Endocrinol Metab; 2023 Jul; 36(7):643-649. PubMed ID: 37285233
[TBL] [Abstract][Full Text] [Related]
8. New predictive models and indices for screening MAFLD in school-aged overweight/obese children.
Xing Y; Zhang P; Li X; Jin S; Xu M; Jia J; Wang HJ; Li L; Wang H
Eur J Pediatr; 2023 Nov; 182(11):5025-5036. PubMed ID: 37648793
[TBL] [Abstract][Full Text] [Related]
9. Updated upper limits of normal serum alanine aminotrasferase levels for screening metabolic dysfunction-associated fatty liver disease in obese children.
Lin YC; Chang PF; Ni YH
J Formos Med Assoc; 2022 Dec; 121(12):2548-2555. PubMed ID: 35738972
[TBL] [Abstract][Full Text] [Related]
10. Estimating global prevalence, incidence, and outcomes of non-alcoholic fatty liver disease from 2000 to 2021: systematic review and meta-analysis.
Liu J; Tian Y; Fu X; Mu C; Yao M; Ni Y; Liu Y; Li Z
Chin Med J (Engl); 2022 Jul; 135(14):1682-1691. PubMed ID: 36070463
[TBL] [Abstract][Full Text] [Related]
11. Impact on Prevalence of the Application of NAFLD/MAFLD Criteria in Overweight and Normal Weight Patients.
Ordoñez-Vázquez AL; Juárez-Hernández E; Zuarth-Vázquez JM; Ramos-Ostos MH; Uribe M; Castro-Narro G; López-Méndez I
Int J Environ Res Public Health; 2022 Sep; 19(19):. PubMed ID: 36231529
[TBL] [Abstract][Full Text] [Related]
12. Global Prevalence and Clinical Characteristics of Metabolic-associated Fatty Liver Disease: A Meta-Analysis and Systematic Review of 10 739 607 Individuals.
Chan KE; Koh TJL; Tang ASP; Quek J; Yong JN; Tay P; Tan DJH; Lim WH; Lin SY; Huang D; Chan M; Khoo CM; Chew NWS; Kaewdech A; Chamroonkul N; Dan YY; Noureddin M; Muthiah M; Eslam M; Ng CH
J Clin Endocrinol Metab; 2022 Aug; 107(9):2691-2700. PubMed ID: 35587339
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of non-alcoholic fatty liver disease in overweight and obese children seeking ambulatory healthcare in Nairobi, Kenya.
Mburu AN; Laving A; Macharia WM; Sande J
BMJ Open Gastroenterol; 2023 Feb; 10(1):. PubMed ID: 36796875
[TBL] [Abstract][Full Text] [Related]
14. Comparative Burden of Metabolic Dysfunction in Lean NAFLD vs Non-lean NAFLD - A Systematic Review and Meta-analysis.
Tang A; Ng CH; Phang PH; Chan KE; Chin YH; Fu CE; Zeng RW; Xiao J; Tan DJH; Quek J; Lim WH; Mak LY; Wang JW; Chew NWS; Syn N; Huang DQ; Siddiqui MS; Sanyal A; Muthiah M; Noureddin M
Clin Gastroenterol Hepatol; 2023 Jul; 21(7):1750-1760.e12. PubMed ID: 35863685
[TBL] [Abstract][Full Text] [Related]
15. An Observational and Cross-Sectional Study of the Prevalence of Breast Lesions and Metabolic Dysfunction-Associated Fatty Liver Disease and their Relationship in China.
Li S; Xu Z; Li H; Tang J; Liang XY; Tian S; Wu J; Li X; Liu ZL; Xiao J; Chen YL; Wei JY; Ma CY; Wu KN; Ran L; Kong LQ
J Gastrointestin Liver Dis; 2022 Mar; 31(1):31-39. PubMed ID: 35306559
[TBL] [Abstract][Full Text] [Related]
16. Editorial: International Consensus Recommendations to Replace the Terminology of Non-Alcoholic Fatty Liver Disease (NAFLD) with Metabolic-Associated Fatty Liver Disease (MAFLD).
Méndez-Sánchez N; Díaz-Orozco LE
Med Sci Monit; 2021 Jul; 27():e933860. PubMed ID: 34248137
[TBL] [Abstract][Full Text] [Related]
17. Systematically comparing epidemiological and clinical features of MAFLD and NAFLD by meta-analysis: Focusing on the non-overlap groups.
Ayada I; van Kleef LA; Alferink LJM; Li P; de Knegt RJ; Pan Q
Liver Int; 2022 Feb; 42(2):277-287. PubMed ID: 34953098
[TBL] [Abstract][Full Text] [Related]
18. An Observational Data Meta-analysis on the Differences in Prevalence and Risk Factors Between MAFLD vs NAFLD.
Lim GEH; Tang A; Ng CH; Chin YH; Lim WH; Tan DJH; Yong JN; Xiao J; Lee CW; Chan M; Chew NW; Xuan Tan EX; Siddiqui MS; Huang D; Noureddin M; Sanyal AJ; Muthiah MD
Clin Gastroenterol Hepatol; 2023 Mar; 21(3):619-629.e7. PubMed ID: 34871813
[TBL] [Abstract][Full Text] [Related]
19. Fatty liver with metabolic disorder, such as metabolic dysfunction-associated fatty liver disease, indicates high risk for developing diabetes mellitus.
Miyake T; Matsuura B; Furukawa S; Ishihara T; Yoshida O; Miyazaki M; Watanebe K; Shiomi A; Nakaguchi H; Yamamoto Y; Koizumi Y; Tokumoto Y; Hirooka M; Takeshita E; Kumagi T; Abe M; Ikeda Y; Iwata T; Hiasa Y
J Diabetes Investig; 2022 Jul; 13(7):1245-1252. PubMed ID: 35167194
[TBL] [Abstract][Full Text] [Related]
20. Trends in prevalence and all-cause mortality of metabolic dysfunction-associated fatty liver disease among adults in the past three decades: Results from the NHANES study.
Xie ZQ; Li HX; Wang BK; Yang ZM; Zhang ZY; Tan WL; Li WX; Wang QB; Yang L; Zhuang HK; Tang CW; Shang CZ; Chen YJ
Eur J Intern Med; 2023 Apr; 110():62-70. PubMed ID: 36754655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
